Botulinum toxin-a therapy in pediatric population - single-center experience
Open Access
- 1 January 2024
- journal article
- Published by National Library of Serbia in Medicinski Pregled
- Vol. 77 (7-8) , 216-221
Abstract
Introduction. This study aims to evaluate the efficacy and safety of Botulinum toxin-A therapy in pediatric population with lower urinary tract symptoms. Material and Methods. A retrospective review was conducted on our initial clinical experience in treating lower urinary tract symptoms with Botulinum toxin-A at the Institute for Child and Youth Health Care of Vojvodina. Given the diversity of symptoms and the heterogeneity of underlying pathological conditions, each patient and their treatment outcomes were individually analyzed. Results. Our clinical experience revealed that 80% of the patients demonstrated significant improvement in symptoms following Botulinum toxin-A injections. Specifically, of the 17 patients treated, 15 reported symptom relief, with 7 achieving complete regression of lower urinary tract symptoms. Only two patients with developmental delays exhibited partial improvement, with persistent lower urinary tract symptoms. Conclusion. Botulinum toxin-A injections have shown promising efficacy in managing refractory bladder dysfunction in the pediatric population. The majority of patients experienced symptom regression, with many achieving complete remission. The treatment protocol was well-tolerated, with no adverse effects observed. However, the variability in treatment responses, particularly in patients with developmental delays, underscores the need for individualized treatment planning. Larger cohort studies with extended follow-up periods are needed to validate the longterm efficacy and safety of Botulinum toxin-A therapy in pediatric population. Among available therapeutic options, Botulinum toxin-A plays a significant role in improving the quality of life for children with lower urinary tract symptoms.Keywords
This publication has 16 references indexed in Scilit:
- Mixed urinary incontinence: Are there effective treatments?Neurourology and Urodynamics, 2022
- Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladderJournal of Pediatric Urology, 2022
- EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatmentNeurourology and Urodynamics, 2019
- Daytime urinary incontinence in children and adolescentsThe Lancet Child & Adolescent Health, 2019
- Urinary IncontinencePrimary Care: Clinics in Office Practice, 2019
- The prevalence of urinary incontinenceClimacteric, 2018
- The Management of the Pediatric Neurogenic BladderCurrent Bladder Dysfunction Reports, 2016
- The management of childhood urinary incontinencePediatric Nephrology, 2014
- Biofeedback Therapy for Dysfunctional Voiding in ChildrenCurrent Urology Reports, 2011
- Biofeedback therapy and dysfunctional voiding in childrenCurrent Urology Reports, 2003